Sunday, November 13, 2016

BRIEF-Novartis gets FDA priority review status for PKC412

* Says pkc412 (midostaurin) granted FDA priority review for

newly-diagnosed flt3-mutated aml and advanced systemic

mastocytosis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)